Lenacapavir
Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.
It is given by mouth and as a subcutaneous injection. The most common side effects include reactions at the injection site and nausea. Lenacapavir was first authorized for medical use in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022.
It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. The FDA considers it to be a first-in-class medication. In 2025, lenacapavir was approved for HIV prevention (PrEP) in the United States, the European Union, and Canada and introduced in China.
In 2026, it became available for PrEP as Yeytuo in Australia. India has sought a waiver to bring faster approval for its use as PrEP in the country based on existing evidence, and Indian generic manufacturers have entered into a voluntary licensing agreement with Gilead Sciences to make the medication available at low cost to high priority countries in a "global access strategy".
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376983477 under CC BY-SA 4.0; modifications have been made.